These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 22059392

  • 1. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
    Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A.
    Helicobacter; 2011 Dec; 16(6):420-6. PubMed ID: 22059392
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
    Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L.
    Dig Liver Dis; 2010 Feb; 42(2):110-4. PubMed ID: 19846355
    [Abstract] [Full Text] [Related]

  • 3. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
    Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Haferland C, Bästlein E, Jebens C, Zekorn C, Knoth H, Stolte M, Lehn N.
    Helicobacter; 2008 Feb; 13(1):69-74. PubMed ID: 18205669
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
    Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH.
    BMC Gastroenterol; 2013 Sep 19; 13():138. PubMed ID: 24050512
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
    Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS.
    Helicobacter; 2009 Oct 19; 14(5):77-85. PubMed ID: 19751431
    [Abstract] [Full Text] [Related]

  • 7. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
    Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS.
    Helicobacter; 2007 Dec 19; 12(6):623-8. PubMed ID: 18001404
    [Abstract] [Full Text] [Related]

  • 8. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
    Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, Kuo YH, Lin MT, Lee CH, Hsu CN, Wu KL, Hu TH, Chuah SK.
    J Antimicrob Chemother; 2019 Jun 01; 74(6):1718-1724. PubMed ID: 30768161
    [Abstract] [Full Text] [Related]

  • 9. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
    Nista EC, Candelli M, Zocco MA, Cazzato IA, Cremonini F, Ojetti V, Santoro M, Finizio R, Pignataro G, Cammarota G, Gasbarrini G, Gasbarrini A.
    Aliment Pharmacol Ther; 2005 May 15; 21(10):1241-7. PubMed ID: 15882245
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N.
    World J Gastroenterol; 2015 May 14; 21(18):5568-74. PubMed ID: 25987781
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, Kim N, Jung HC.
    World J Gastroenterol; 2014 Jun 14; 20(22):6932-8. PubMed ID: 24944485
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X, Li Y, Qiu Y, Tang Q, Qian B, Yao L, Shi R, Zhang G.
    Clin Ther; 2010 Nov 14; 32(12):2003-11. PubMed ID: 21118735
    [Abstract] [Full Text] [Related]

  • 19. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP, Romano M, Molina-Infante J, Lucendo AJ, Medina E, Modolell I, Rodríguez-Tellez M, Gomez B, Barrio J, Perona M, Ortuño J, Ariño I, Domínguez-Muñoz JE, Perez-Aisa Á, Bermejo F, Domínguez JL, Almela P, Gomez-Camarero J, Millastre J, Martin-Noguerol E, Gravina AG, Martorano M, Miranda A, Federico A, Fernandez-Bermejo M, Angueira T, Ferrer-Barcelo L, Fernández N, Marín AC, McNicholl AG.
    Dig Liver Dis; 2015 Feb 14; 47(2):108-13. PubMed ID: 25454706
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH.
    Helicobacter; 2012 Oct 14; 17(5):374-81. PubMed ID: 22967121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.